



April 24, 2017

BioCryst to Announce First Quarter 2017 Financial Results May 4

RESEARCH TRIANGLE PARK, N.C., April 24, 2017 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017.

BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by [Jon P. Stonehouse, President & Chief Executive Officer](#), Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB[®] (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910

 Primary Logo

Source: BioCryst Pharmaceuticals

News Provided by Acquire Media